The Year Is Done!
The year is done, and it is a challenge to find the bright spots. There are a few – some tech giants did well in addition to specialized pharma. With pharma in particular, cheap loans sponsored by the Fed’s policy, M&A activity drove most of the gains to be seen in the market. The overall […]